Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics

T cells redirected to cancer cells either via a chimeric antigen receptor (CAR-T) or a bispecific molecule have been breakthrough technologies; however, CAR-T cells require individualized manufacturing and bispecifics generally require continuous infusions. We created an off-the-shelf, single-dose s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cripe, Timothy P., Hutzen, Brian, Currier, Mark A., Chen, Chun-Yu, Glaspell, Andrea M., Sullivan, Grace C., Hurley, Julia M., Deighen, Mackenzie R., Venkataramany, Akila S., Mo, Xiaokui, Stanek, Joseph R., Miller, Anthony R., Wijeratne, Saranga, Magrini, Vincent, Mardis, Elaine R., Mendell, Jerry R., Chandler, Dawn S., Wang, Pin-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278853/
https://www.ncbi.nlm.nih.gov/pubmed/35857488
http://dx.doi.org/10.1126/sciadv.abm1890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278853/
https://www.ncbi.nlm.nih.gov/pubmed/35857488
http://dx.doi.org/10.1126/sciadv.abm1890

Ejemplares similares